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Abstract
Accurate estimates of malaria vaccine efficacy require a reliable definition of a
malaria case. However, the symptoms of clinical malaria are unspecific, overlapping
with other childhood illnesses. Additionally, children in endemic areas tolerate varying
levels of parasitemia without symptoms. Together, this makes finding a gold-standard
case definition challenging. We present a method to identify and estimate malaria
vaccine efficacy that does not require an observable gold-standard case definition. In-
stead, we leverage genetic traits that are protective against malaria but not against
other illnesses, e.g., the sickle cell trait, to identify vaccine efficacy in a randomized
trial. Inspired by Mendelian randomization, we introduce Mendelian factorial design, a
method that augments a randomized trial with genetic variation to produce a natural
factorial experiment, which identifies vaccine efficacy under realistic assumptions. A
robust, covariance adjusted estimation procedure is developed for estimating vaccine
efficacy on the risk ratio and incidence ratio scales. Simulations suggest that our es-
timator has good performance whereas standard methods are systematically biased.
We demonstrate that a combined estimator using both our proposed estimator and the
standard approach yields significant improvements when the Mendelian factor is only
weakly protective.
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1 Introduction
In 2017, there were an estimated 219 million cases of malaria of which 92% occurred in Africa
and an estimated 435,000 malaria related deaths of which 93% occurred in Africa; nearly
every case of malaria in Africa was cause by the parasite Plasmodium falciparum (World
Health Organization, 2018). Pregnant women and children under the age of 5 are the most
vulnerable groups affected by malaria. To date, of more than 30 vaccines under development,
the only vaccine to undergo a pivotal phase III trial is the pre-erythrocytic vaccine RTS,S
which has shown to have limited efficacy (30− 50% reduction in incidence rates; Mahmoudi
and Keshavarz (2017)). Consequently, the continued development of an efficacious P. fal-
ciparum malaria vaccine has the potential for substantial public health impacts. With so
many potential vaccines in the development pipeline, a critically important statistical chal-
lenge is to develop methods for estimating vaccine efficacy. To date, accurate estimation
of vaccine efficacy against clinical outcomes attributable to P. falciparum malaria requires
defining reliable case definitions, a task that is made difficult by the unspecific presentation
of malaria in endemic areas.
In the absence of a gold standard case definition, efficacy is usually assessed by choosing
an inexact case definition which may falsely exclude cases attributable malaria and falsely
include non-malaria cases. The established definition of clinical malaria in malaria prevention
trials is the presence of a fever with a temperature ≥ 37.5oC and a P. falciparum parasite
density above a certain threshold, e.g., 2500 or 5000 parasites per µl of blood (Ter Kuile
et al., 2003; The RTS,S Clinical Trials Partnership, 2011; Olotu et al., 2013; Bejon et al.,
2013). Case definitions of this form inevitably exclude some true cases and include some false
cases due to heterogeneity in immunity and endemicity, fever killing effects, and parasite
density measurement error. With specificity < 1, estimates of vaccine efficacy will be biased
downward. It has been shown in simulations that such case classification errors have the
potential to introduce substantial bias in many settings (Small et al., 2010). Real trial data
suggests that these challenges with the standard case definition often go unaddressed. In
a multi-site pooled analysis of phase II RTS,S trial data using a fixed 2500 parasite per µl
cutoff across all study sites, Bejon et al. (2013) reports estimates of vaccine efficacy against
malaria that were as high as 60% in sites with low parasite prevalence and as low as 4% in high
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parasite prevalence sites. The authors suggest a biological reason for this pattern: RTS,S
prevents fevers in only a portion of mosquito bites and in areas where parasite prevalence
is high, children are likely bitten more often by infected mosquitos. However this pattern is
also consistent with bias due to the fixed case definition having lower specificity in higher
prevalence areas where, due to improved immunity, children can carry higher parasite loads
without fever. The standard case definition leaves much unanswered: is the heterogeneity
in vaccine efficacy epidemiologically important or just an artifact of bias arising from an
inexact case definition?
To overcome the challenges that accompany inexact case definitions, this paper introduces
a new method for identifying malaria vaccine efficacy using natural genetic variation, which
we call Mendelian factorial design. Importantly, the method does not depend on an inexact
case definition based on the parasite density, instead using all fevers (or deaths) with any
level of parasitemia to estimate efficacy. To identify vaccine efficacy, the new method requires
finding and recording genetic variants that provide specific protection against clinical malaria
and operate through a different biological pathway than the vaccine being evaluated. A
running example in this paper is the sickle cell trait, a hemoglobinopathy that has been shown
to protect against malaria at the blood-stage (erythrocytic) of the infection and the RTS,S
vaccine, which confers protection against malaria at the pre-erythrocytic, liver-stage of the
infection. There are many other vaccine types, e.g., transmission blocking and erythrocytic
vaccines, and genetic variants that might satisfy these identifying conditions (Ndila et al.,
2018). We will discuss these occasionally throughout the paper and more thoroughly in the
discussion.
In the following section, we introduce Mendelian factorial design informally in the context
of the more familiar use of genetic variants as instrumental variables in Mendelian random-
ization studies, to which it has many parallels. In §3, we present a precise definition of
vaccine efficacy and malaria-attributable fevers in a potential outcome framework and pro-
pose an identification strategy that holds under a few realistic assumptions. We then provide
a simple
√
n-consistent and asymptotically normal covariate-adjusted estimator that is ro-
bust to model misspecification and assess its performance in a simulation study over a range
of settings. We develop an improved “bounded" estimator that combines the strengths of
our estimator with that of the (biased) standard estimator. We demonstrate that it provides
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nearly uniform improvement over both estimators. In Appendix A of the Supplemental Web
Materials we extend the Mendelian factorial design to identify and estimate vaccine efficacy
in time-to-first event studies.
2 Mendelian Factorial Design: Parallels with Mendelian
Randomization
When an observed association between a non-randomized exposure and an outcome may be
confounded by an unobserved common cause, attributing the association to a causal effect
may be misleading (Rosenbaum, 2002). An instrumental variable (IV) is a covariate that is
associated with the exposure but whose only association to the outcome is through a direct
pathway to the exposure (Martens et al., 2006). The IV takes the place of the physical
randomization in a randomized trial, influencing only the assignment of subjects to exposure
or control, setting up a natural experiment and providing an avenue for estimating the
causal effect of the non-randomized exposure on the outcome (Rassen et al., 2009). When
genetic variants are used as instrumental variables, the corresponding collections of methods
are often labeled as the Mendelian randomization (MR) approach (Smith and Ebrahim,
2008). For example, Kang et al. (2013) proposed using the hemoglobin S variant (HbS)
as an instrument to identify the causal effect of malaria on stunted growth. It is known
that heterozygote carriers (HbAS, sickle cell trait) receive protection against clinical malaria
whilst those without the variant (HbAA) do not. The first column of Table 1 summarizes
the assumptions required of HbAS status such that it can be used in a MR study to identify
the causal effect of malaria on stunting. Assumption (1) requires that HbAS status in fact
influences exposure; assumption (2) ensures that HbAS status can be treated “as-if" it were
randomized; and assumption (3) says that HbAS only effects stunted growth through its
influence on exposure. Assumption (4) is required for point identification of the causal
effect, although there are other alternative assumptions that can be used to point identify a
causal effect such as monotonicity of the effect (Burgess et al., 2017).
Like MR, Mendelian factorial design (MFD) leverages genetic variation to identify a
causal effect of interest – in this instance, the efficacy of a vaccine, or roughly, the propor-
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Table 1: Parallel assumptions for Mendelian randomization and Mendelian factorial design.
Assumption Mendelian Randomization Mendelian Factorial Design
(1) •HbAS associated with
malaria
• HbAS has protective efficacy
against malaria-attributable fever
(2) • No unmeasured con-
founders associated with
HbAS and stunted growth
• HbAS “as-if" randomized
(3) • Only direct pathway from
HbAS to stunted growth is
through malaria
• Protection provided by HbAS
is specific to malaria-attributable
fever
(4) • HbAS does not mod-
ify the effect of malaria on
stunting
• No interaction effect between
HbAS and vaccine (i.e., indepen-
dent protective pathways)
tion reduction of disease-attributable outcomes in a population when the vaccine is applied
(Lachenbruch, 1998). However, instead of addressing the bias that often accompanies a
non-randomized exposure, MFD attends to the bias in estimating treatment efficacy arising
from an inexact case definition. The natural experiment arising from MR is used for causal
inference in the absence of an actual randomized experiment, enabling the investigator to
distinguish causal effects from unobserved confounding. The same natural experiment is
employed in MFD to augment a two-arm randomized trial and create a simple 2× 2 facto-
rial experiment. The factorial design allows the investigator to distinguish efficacy against
disease-attributable outcomes even when the case definition incorrectly classifies a material
number of non-disease outcomes as cases.
Although MR and MFD address different sources of bias in different settings, their designs
share many parallel features. This is illustrated in Table 1, where each assumption of MR
in the malaria stunting study corresponds to a closely related assumption that underlies a
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MFD study of vaccine efficacy against malaria-attributable fever. In more general terms,
Assumption (1) says that the Mendelian gene or Mendelian factor, e.g., HbAS, is relevant.
In the MR study this means that it is associated with the non-randomized exposure and
in the MFD study this implies that the Mendelian gene is protective against the disease-
attributable outcome. Assumption (2) requires that the Mendelian gene be unconfounded
with the outcome of interest or be “as-if" randomized, which implies the former. For the MR
study, assumption (3) says that the Mendelian gene has no pleiotropic effects (Smith and
Ebrahim, 2008), that is, HbAS only effects stunted growth through its influence on malaria
and not through its influence on another modifiable exposure or stunting itself. The parallel
assumption for a MFD study is that the Mendelian factor protects against outcomes of any-
cause only through reducing disease-attributable outcomes. Finally, assumption (4) says
that the causal effect in the MR study does not vary over different levels of the Mendelian
gene, or in other words, they do not interact. Similarly, the corresponding assumption in a
MFD study is that the vaccine and Mendelian factor do not interact. In other words, the
vaccine prevents the same proportion of disease-attributable outcomes at different levels of
the Mendelian gene. For example, this assumption is plausible when a malaria vaccine and
HbAS provide protection against malaria-attributable fevers through independent biological
pathways.
Assumptions (1)-(3) in Table 1 may be better understood encoded in a causal diagram.
The causal diagram for MR and MFD are in the left and right panels of Figure 1, respectively.
G is a Mendelian gene (or factor), U are unobserved confounders, Z is a randomized vaccine,
and E is a non-randomized exposure. Y is the outcome of interest – in the MR study it
is stunted growth and in the MFD study it is clinical malaria. Y m and Y nm are malaria-
attributable and non-malaria fevers, respectively. We define these more precisely in §3.
Finally, the blue arrows indicate the causal quantities of interest and the red arrows indicate
the confounding addressed by each design. The causal diagram for MFD is a little bit
unusual. Y m and Y nm are grayed out, emphasizing that we don’t observed them, but instead
only observe the outcome that is not distinguished by cause, Y . This is represented by the
black bounding box. The MFD diagram hints at how the factorial structure and the absence
of an arrow between G and Y nm may be used to identify the arrow between Z and Y m, the
vaccine efficacy.
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Figure 1: Causal diagrams for MR (left) and MFD (right). Blue arrows indicate the causal
quantities of interest and red arrows indicate confounding addressed by each design. Gray
variables Y m and Y nm are unobservable but Y , which doesn’t distinguish between them is.
Assumptions (1), (2) and (3) correspond to the similarly numbered assumptions in Table 1.
.
3 A Robust Framework for Estimating Vaccine Efficacy:
Risk Ratios and Incidence Rate Ratios
3.1 Notation: Observed Data
Let j = 1, . . . , J indicate sites in a multi-site randomized control trial (RCT) and i = 1, . . . , Ij
indicate subjects at each center; then, ij uniquely identifies each subject in the study. We
let the total number of subjects in the trial be n =
∑
j Ij. For subject ij, let Yij ∈ {0, 1} be
an observed fever or death with any parasitemia; let Zij ∈ {0, 1} indicate treatment/vaccine
status and Gij ∈ {0, 1} indicate sickle cell variant status (Gij = 1 if HbAS, Gij = 0 if
HbAA); and let Xij ∈ Rd be a d-dimensional vector of baseline characteristics. Because
G is assigned at conception, careful consideration of what variables constitute “baseline"
variables should be made. Let Dij and Uij indicate the malaria parasite density in the
blood and the level of non-malaria infectious agents, respectively. Define the observed data
vector Oij = (Xij, Zij, Gij, Yij). While Uij is generally not observed in malaria trials, Dij is.
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However, because the methods developed in this paper do not require or explicitly model
parasite density we omit it from Oij. We drop the subscripts and write O = (X,Z,G, Y )
to denote a random draw from a specified population. We will use boldface to indicate
corresponding vector and matrix quantities that collect the data of subjects over each site
or the entire trial. For example, Yj is the Ij × 1 vector that collects all the outcome data
for subjects at site j and Y = (YT1 , . . . ,YTJ )T is the n× 1 vector that collects the outcome
data for all subjects in the multi-site trial. For an example of a matrix quantity, Xj is an
Ij × d matrix and X is a n× d matrix.
Multi-site RCTs, i.e., block randomized, are a common design for vaccine efficacy trials,
such as the Phase III RTS,S trial (The RTS,S Clinical Trials Partnership, 2011). Another
design that has commonly been employed in studying the protective efficacy of interventions
such as insecticide treated bed nets is the clustered RCT (Ter Kuile et al., 2003). The
notation is easily adapted for this design, letting j indicate a cluster and Zij = Zj for all i, j.
3.2 Potential Outcomes and Malaria-Attributable Fever (or Death)
3.2.1 Pitfalls of Standard Case Definitions
The standard case definition of clinical malaria is the presence of a fever (Y = 1) and a
parasite density above some threshold d (D > d). The WHO recommends setting d high
enough to achieve specificity > 80% at all sites to avoid severe underestimation of vaccine
efficacy (Moorthy et al., 2007). Sensitivity is also considered when determining d to avoid
under-powered studies. The prevailing method used to determine these thresholds is to
model risk of fever as a continuous function of observed parasite density among community
controls and clinically suspected cases (Smith et al., 1994). However, computing sensitivity
and specificity of a case definition requires an estimate of the malaria attributable fraction
of fevers (MAFF). Lee and Small (2018) show that obtaining unbiased estimates of MAFF
in the presence of measurement error of D and fever killing effects on parasite density is a
difficult task, especially when malaria and non-malaria infections can work in conjunction to
trigger a fever. Still, when unbiased estimates of MAFF can be obtained, this case definition
will, by design, result in false positive and false negative cases, which may bias corresponding
estimates of vaccine efficacy. Heterogeneous immunity and pyrogenic thresholds further com-
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plicate estimating treatment efficacy using case definitions that depend on a fixed threshold
for D. In practice, standard thresholds without, it seems, careful estimation of specificity
and sensitivity such as 2500 parasites per µl (Olotu et al., 2013) and 5000 parasites per µl
are commonly used (The RTS,S Clinical Trials Partnership, 2011). As far as we are aware,
there are no sufficiently specific case-definitions for death attributable to malaria, the most
severe effect of a malaria infection (Moorthy et al., 2007).
3.2.2 Defining Cases Using Potential Outcomes
Potential outcomes are a useful framework to precisely define causal effects of interest (Rubin,
2005). The potential outcomes that we define now are closely related to those defined in Lee
and Small (2018). In what follows, we consider Y to indicate the presence of fever but note
that the framework we describe is also suitable when Y indicates death. The aforementioned
authors motivate their framework with a biological model of malaria and the notion of a
pyrogenic threshold (Gravenor and Kwiatkowski, 1998). A pyrogenic threshold can roughly
be defined as a level of malaria parasite density above which a fever will be produced. Below
the threshold, the infection will not be strong enough to trigger a fever. This threshold
may vary from individual to individual based on heterogeneous immunity to symptomatic
malaria. In general, we can think of D and U as having thresholds above which a malaria or
non-malaria infection, respectively, is strong enough to trigger a fever in the absence of any
other infection. We can also consider a curve of threshold pairs for D and U above which a
combined infection can trigger a fever.
Because Y indicates the presence of a fever resulting from any infection, we can treat Y as
a function of both D and U . Y can be thought of also as a function of Z and G through their
effect on D and U . Thus, we can write the potential outcome of Y for treatment z and sickle
cell status g as Y (D(z, g), U(z, g)) and the observed outcome as Y = Y (D(Z,G), U(Z,G)).
Y (D(z, g), U(z, g)) factors additively into two natural terms,
Y (D(z, g), U(z, g))︸ ︷︷ ︸
Y (z,g)
= {Y (D(z, g), U(z, g))− Y (0, U(z, g))}︸ ︷︷ ︸
Ym(z,g)
+Y (0, U(z, g))︸ ︷︷ ︸
Y nm(z,g)
. (1)
Y can be expressed as a potential outcome in terms of d and u or z and g. When it
is unambiguous, we may use the abbreviated notation below the “curly” braces in (1) to
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emphasize its dependence on z and g.
The statistical implication of a pyrogenic threshold is that Y (d, u) is monotonic in d for
all u. That is, Y (d, u) ≤ Y (d′, u) for 0 ≤ d ≤ d′. This ensures that the first term on the
right hand side of (1) is non-negative. This term, Y m(z, g), can be interpreted as malaria-
attributable fever, or a fever that would not have occurred had a malaria infection been
absent. These include cases where D was high enough to trigger a fever in the absence of any
other infection and also cases where D was high enough to trigger a fever in conjunction with
a non-malaria infection. The second term on the right hand side, Y nm(z, g), is a fever that
cannot be attributed to malaria. These are fevers that would have still occurred if malaria
parasites were not present. However, when D > 0, Y m(Z,G) is generally not observable
because it involves the counterfactual term Y (0, U(Z,G)). In the following section we will
demonstrate that under a few realistic assumptions we can identify vaccine efficacy without
directly observing the fevers (or deaths) attributable to malaria.
3.2.3 A Final Couple Pieces of Notation
With our potential outcome framework in place, we denote the complete data vector by
C = (X,Z,G,D,U, {Y k(z, g) : k = m,nm; z = 0, 1; g = 0, 1}) .
In reality, we only get to observe one potential outcome Y (Z,G) even though all four exist
and, as we have argued, Y nm and Y m cannot be distinguished with certainty so we only
observe O ⊂ C. Finally, we may sometimes treat Y , D and U as p × 1 vectors that
correspond to fever status, parasite density, and non-malaria infectious load at p follow-up
visits during a RCT.
3.3 Vaccine Efficacy: Definitions, Assumptions and Identification
3.3.1 Defining Vaccine Efficacy
We begin this section by defining a general population-level estimand for vaccine efficacy
and then outline the assumptions required for identification when we cannot distinguish Y m
from Y nm. We suppose that for each j, Cij (and Oij) are i.i.d. draws from an from an
unknown, site-specific target population distribution Pj ∈ Pj for all i. We suppose that the
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overall target population is an equally weighted mixture of the Pj and denote it P ∈ P . We
let µzg(P ), P → R be a functional of P that depends on treatment and sickle cell status and
takes the form µzg(P ) = EP [f{Y (z, g)}] for P -measurable functions f that are (1) increasing
and (2) linear. We use a superscript m to indicate that the functional is specific to malaria-
attributable outcomes and nm to indicate that it is specific to non-malaria outcomes, for
instance, µmzg(P ) = EP [Y m(z, g)] when f(y) = y. Below we give a general definition of
efficacy.
Definition 1 (Vaccine/Protective Efficacy). For a specified function f ,
(i) Vaccine Efficacy is defined as τ(g) = 1− µm1g(P )/µm0g(P ) for g = 0, 1 and
(ii) Protective Efficacy of G is defined as ν(z) = 1− µmz1(P )/µmz0(P ) for z = 0, 1.
We are primarily interested in two simple functions f : f(y) = y and when Y is a p × 1
vector of fevers, f(y) = 1Ty. For f(y) = y , efficacy as defined in Definition 1 is the
proportion reduction in risk of malaria-attributable fever or death were an individual to
receive vaccination versus placebo. For f(y) = 1Ty, efficacy is defined as the proportion
reduction in incidence of malaria-attributable fever were an individual to receive vaccination
versus placebo. Since you can only die once, f(y) = 1Ty is not applicable when Y indicates
malaria-attributable death. By this same logic, f(y) = y can be used for assessing the risk
of malaria-attributable deaths over arbitrarily long follow-up. However, if we are interested
in the risk of developing a malaria-attributable fever over a longer follow-up, during which
a subject can have multiple fevers, the function we’d be interested in is f(y) = max y where
max y is the maximum over the elements of a p × 1 vector y. This function is not a linear
function and thus vaccine efficacy against the risk of having at least one malaria-attributable
fever over a long follow cannot be handled in this framework. The importance of the linearity
of f will become evident shortly.
3.3.2 Identifying Vaccine Efficacy
In §2 we informally discussed the assumptions required to identify vaccine efficacy using
MFD. Assumptions 1 - 5 formalize the assumptions that are summarized in the second
column of Table 1 and provide the basis for the identification of τ proved in Proposition 1.
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Assumption 1 (Additivity of µ). For all z = 0, 1 and g = 0, 1, µzg(P ) can be decomposed
linearly as
µzg(P ) = µ
m
zg(P ) + µ
nm
gz (P ) .
Assumption 1 is guaranteed by (1) and the linearity of f . We mentioned above that
evaluating the vaccine efficacy on the risk scale for malaria-attributable fevers over a long
follow-up is problematic when using MFD to estimate τ . The risks of developing a malaria-
attributable fever and a non-malaria fever do not satisfy Assumption 1 over long follow-ups
because of the non-linearity of f(y) = max y.
Assumption 2 (No Interaction / Independent Protective Pathways). τ(g) is constant over
g = 0, 1 and ν(z) is constant over z = 0, 1. That is, τ := τ(0) = τ(1) and ν := ν(0) = ν(1).
The biological reasoning behind Assumption 2 is as follows. If a vaccine and genetic trait
protect against malaria through independent pathways at different times in the parasite’s
life cycle, it is plausible that the vaccine will prevent the same fraction of fevers among those
who have the genetic trait (G = 1) and those who do not (G = 0). Similarly plausible is
that possession of the genetic trait will prevent the same fraction of fevers among those to
whom the vaccine was administered (Z = 1) and to those it was not (Z = 0). The goal
of pre-erythrocytic vaccines like RTS,S is to provoke an immune response that prevents the
parasites from entering the liver, stopping the parasites from ever re-entering the bloodstream
and causing clinical symptoms (Regules et al., 2011). In contrast, the sickle cell trait appears
to protect against clinical symptoms by inhibiting the growth of parasites once they have
re-entered the bloodstream from the liver and by making the host more tolerant to parasite
infection (Ferreira et al., 2011; Taylor et al., 2012; Williams, 2011). This suggests that
Assumption 2 is satisfied for pre-erythrocytic vaccines and the sickle cell trait.
Assumption 3 (No Interference). A subject’s potential outcomes are functions of its vaccine
and sickle cell status alone. That is Yij(z,g) = Yij(zij, gij).
Assumption 3 implies that the treatment and sickle cell status of an individual in the
trial effects only their own outcome. This assumption can be rephrased in the context of in-
fectious disease as stating that protection conferred by genetics or vaccine do not materially
disrupt disease transmission. This assumption is plausible when considering individuals at
two different sites j 6= j′ in a multi-site trial but is more complicated for individuals at the
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same site who may live in close proximity. Stochastic simulation models of malaria vaccina-
tion using pre-erythrocytic and blood stage-vaccines have, however, found that transmission
effects of such vaccines delivered as they would be in pediatric malaria vaccination programs
were minimal (Penny et al., 2008, 2015). Less is known about the suitability of Assumption
3 with respect to the sickle cell variant.
Assumption 4 (Randomization / “as-if” Randomized). At each site j = 1, . . . , J , vaccines
are administered randomly and sickle cell status is distributed “as-if” random; that is,
(Z,G) ⊥⊥ (Y (z, g), Y m(z, g), Y nm(z, g), X)
for all z, g ∈ {0, 1}2. Additionally, we assume that Z ⊥⊥ G.
The randomization of Z is ensured by the RCT. We assume that within each center, the
sickle cell trait is distributed “as-if” random. Population stratification and linkage disequilib-
rium are common biological violations of the “as-if” random assumption of Mendelian genes
(Kang et al., 2013). Briefly, population stratification is when a subgroups that differ on prog-
nostic factors for developing malaria and other childhood illnesses also systematically differ
in the prevalence of HbAS. If either the probability of inheriting HbAS or the distribution of
prognostic factors is relatively homogenous within a study site, then population stratification
would likely not be a material threat to the “as-if” random assumption about G. Linkage
disequilibrium is the dependence of gene frequencies at two or more loci (Morton, 2001). If
HbAS is in linkage disequilibrium with a gene that affects the risk of childhood illness this
may threaten the validity of Assumption 4. Linkage disequilibrium with a gene that affects
the risk of malaria is less problematic as this would not violate the exclusion restriction
formalized in the next assumption. However, this would require a more delicate treatment
of potential outcomes, e.g., we would need to consider the genes in linkage disequilibrium
as having potential outcomes depending on G (see VanderWeele and Hernan (2013) for a
discussion a related topic of “versions" of treatment).
Assumption 5 (Valid Mendelian Factor). G is a “valid Mendelian factor” in that it satisfies
the following conditions:
(i) ν 6= 0; and
(ii) 1− µnmz1 (P )/µnmz0 (P ) = 0 for z = 0, 1.
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Part (i) of Assumption 5 says that the Mendelian factor is relevant to malaria-attributable
outcomes. A large body of literature on the protective properties of the sickle cell trait
against malaria supports this assumption for HbAS. Several cohort studies have found ev-
idence that HbAS has 30-50% efficacy against uncomplicated clinical malaria and multiple
other case-control and cohort studies of Africa have estimated even greater efficacies against
sever malaria cases of 70-90% (see Gong et al. (2013) for a list of several studies reporting
the protective efficacy of HbAS). Assumption 5(ii) can be expressed in terms of potential
outcomes by the restriction that U depends only on treatment status, U(z, g) = U(z). The
plausibility of Assumption 5(ii) is supported by evidence that the protection conferred by
HbAS is “remarkably specific” to malaria, providing little protection to other childhood dis-
eases (Williams et al., 2005).
The following proposition provides a simple, non-parametric identification strategy for
treatment efficacy as defined in Definition 1 under Assumptions 1 - 5. We also make the
standard assumptions of consistency, that Y = Y (z, g) when Z = z andG = g, and positivity,
that the probability of treatment Z and the prevalence of G in each site are both bounded
away from 0 and 1.
Proposition 1 (Nonparametric Identification). Suppose that Assumptions 1 - 5 are satisfied.
Then the vaccine efficacy τ is identified from the observed data O as
τ = 1− EX [EP [f(Y )|X,Z = 1, G = 1]]− EX [EP [f(Y )|X,Z = 1, G = 0]]
EX [EP [f(Y )|X,Z = 0, G = 1]]− EX [EP [f(Y )|X,Z = 0, G = 0]] , (2)
where EX is the expectation over the marginal distribution of X implied by P .
Proof. The proof of Proposition 1 can be found in Appendix B.1 of the Supplemental Web
Materials.
3.3.3 Remarks
Proposition 1 still holds under a weaker version of Assumption 4 requiring only that Z and G
are independent of potential outcomes (and of each other) conditional on baseline covariates
X. Depending on how rich the set of baseline covariates X is, this weaker assumption may
be more tenable in the presence of population stratification and linkage disequilibrium.
Equation (2) suggests a ratio estimator for τ that is remarkably similar to the Wald esti-
mator used in Mendelian randomization studies (Wald, 1940; Burgess et al., 2017). Without
13
covariates, the Wald estimator of the effect of a non-randomized exposure E on outcome Y
using Mendelian gene G can be written as
Y¯G=1 − Y¯G=0
E¯G=1 − E¯G=0 , (3)
where V¯G=g is the sample average of V for individuals with G = g. Both (2) and (3) involve
ratios of averages differenced over G. The analogy between (2) and the Wald estimator in
(3) is not by coincidence, but instead arises from a symmetry between the structures of
Mendelian randomization with additive effects and Mendelian factorial design with multi-
plicative effects. More precisely, in Mendelian randomization, the potentially confounded
association between the Mendelian gene and the outcome can be decomposed multiplica-
tively into the additive effect of the instrument on the exposure and the additive effect of
the exposure on the outcome. In a Mendelian factorial design, the outcomes can be addi-
tively decomposed into disease-attributable outcomes and non-disease outcomes upon which
the treatment and Mendelian factor have multiplicative effects. This simple structure of
Mendelian factorial design can be seen clearly in the 2× 2 table in Figure 2 of expected out-
comes µzg for different combinations of z and g. Differencing over the columns and taking
the ratio over the rows immediately yields 1− τ . The η term in the top row can be thought
of as the spillover efficacy of the vaccine against non-malaria outcomes. The term drops out
when differencing over the columns.
3.4 Robust Covariance Adjusted Estimation and Inference
We now propose a simple substitution estimator that allows for covariance adjustment and
is robust to arbitrary misspecification of a model for EP [f(Y ) |X,Z,G]. The estimation
procedure closely resembles that which is developed in Rosenblum and van der Laan (2010)
with a couple minor modifications to deal with the factorial structure of our identification
procedure and the possibility that HbAS prevalence varies across sites in a multi-site RCT.
The simple procedure is detailed below in Algorithm 1 and requires estimating a simple
generalized linear model (GLM) with the R function glm in the stats package at most two
times. In what follows, we suppose f(y) = 1Ty for expository purposes. That is, we will
focus on vaccine efficacy defined as the proportion reduction in the expected number of
malaria-attributable fevers.
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g = 1 g = 0
z = 1 µnm(1− η) + µm(1− τ)(1− ν) µnm(1− η) + µm(1− τ)
z = 0 µnm + µm(1− ν) µnm + µm
Figure 2: 2 × 2 table for Mendelian factorial design. Each cell represents µzg(P ) for all
combinations of (z, g) ∈ {0, 1}2, which is identified by the observed data O (Proposition 1).
Differencing over the columns then taking the ratio over the rows yields 1−τ . For notational
clarity, we drop the subscript from µ00. η is the “spillover efficacy” the vaccine may provide
against non-malaria outcomes.
Algorithm 1 (Estimation of τ). The following substitution estimator is based on Rosenblum
and van der Laan (2010). For clarity, we let f(y) = 1Ty.
1. Estimate EP [f(Y ) |X, Z, G] with glm using a canonical link function (depends on f).
• Let the linear part include an intercept, main terms for Z and G, and interaction
Z ×G, for example,
mu_hat_0 <- glm(f(Y) ∼ X*G*Z, family = poisson())
• denote the resulting estimator as µˆ0(Z,G,X).
2. If there is more than one site and the prevalence of G and sample sizes variy across
sites, let log_mu_hat = log µˆ0(Zij, Gij, Xij), p_g = (1/Ij)
∑Ij
i=1Gij, w = n/Ij, and S
be a categorical variable for site; update µˆ0 as follows
mu_hat_1 <- glm(f(Y) ∼ offset(log_mu_hat) + S +
I(w*Z*G/p_g) + I(w*Z*(1-G)/(1-p_g)) + I(w*(1-Z)G/p_g) +
I(w*(1-Z)*(1-G)/(1-p_g)), family = poisson())
and denote the resulting estimator as µˆ1(Z,G,X).
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3. Let µzg(Pn) = 1J
∑J
j=1
1
Ij
∑Ij
i=1 µˆ1(z, g,Xij).
4. Construct the plug-in MFD estimator
τˆ = 1− µ11(Pn)− µ10(Pn)
µ01(Pn)− µ00(Pn) .
The estimator τˆ returned by Algorithm 1 is a special case of a target maximum likelihood
estimator (TMLE) (Van der Laan and Rose, 2011). A straightforward modification of Theo-
rem 1 in Rosenblum and van der Laan (2010) yields that τˆ is consistent and asymptotically
normal under mild regularity conditions even when the working model for the conditional
expectation is misspecified. Other initial working models µˆ0 may be used as long as they
satisfy certain restrictions on how data-adaptive they are (Van der Laan and Rose, 2011).
The weight terms w are important because we assume that the target population P is an
equally weighted mixture of the site-specific populations Pj but allow for study designs with
different different sample sizes across sites. The weights ensure that µˆ1 solves the efficient
influence function estimating equation (see Appendix B.4 of the Supplemental Web Mate-
rials). Before we state the result, we introduce some some important notation and definitions.
Working Models and their Limits:
Let the maximum likelihood parameter estimates from steps 1 and 2 of Algorithm 1 be
β
(0)
n and β(1)n , respectively, and define βn = [β
(0)
n ,β
(1)
n ]. Now, recall that P is the true,
unknown data generating distribution. We can decompose its corresponding density p as
follows as follows
p = p(X)p(Z)pj(G)p(Y |X, Z, G) (4)
where pj(G) is the probability a child has the sickle cell trait in site j. p(Z) is assumed to
be known, e.g., p(Z) = 1/2 in a balanced trial. Pn is our estimate of P where pn, the density
of Pn, can be decomposed similarly as
pn = pn(X)p(Z)pj,n(G)pβn(Y |X, Z, G) (5)
where pn(X) is the empirical distribution of X, pj,n(G) is the observed prevalence of the
sickle cell trait among children in enrolled in the study at site j, and pβn(Y |X, Z, G) is the
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estimated parametric working model for the conditional distribution of Y from steps 1 and 2
in Algorithm 1. We assume that the number of centers are fixed, that they are representative
of the population of interest, and that the sites carry equal weight in the population they
represent but that the sample sizes Ij might be different. Hence, the observations that make
up the empirical distribution are weighted by n/Ij. We assume that the site-level sample
sizes Ij grow at the same rate as n→∞ and so it follows that pn(X) a.s.→ p(X) as n→∞ by
the Gilvenko-Cantelli Theorem and an application of the strong law of large numbers gives
us that pj,n(G)
a.s.→ pj(G) for all j = 1, . . . , J as n → ∞. Let P∞ = limn Pn and write its
density p∞ as
p∞ = p(X)p(Z)pj(G)pβ(Y |X, Z, G) (6)
where β = [β(0),β(1)] are the maximizers of the expected log-likelihoods of the GLMs in steps
1 and 2 where the expectation is taken over P , if such maximizers exist (see Rosenblum
and van der Laan (2010) for further discussion of the existence of β). When β exists,
the conditions given in Proposition 2, are sufficient for βn to converge to β in probability
(Rosenblum and van der Laan, 2009). Note that unless the working parametric model for
the conditional mean is correctly specified, P∞ will not equal P in general.
For notational convenience, we let P and Pn be the expectation operators over P and Pn,
respectively. For example, we can write µzg(Pn) from step 3 of Algorithm 1 as Pnµˆ1(z, g,X).
Efficient Influence Functions:
For an arbitrary distribution Q ∈ P , the efficient influence function (EIF) for µzg(Q) can
be written as
ϕzg(Q)(O) =
1(Z = z)1(G = g)(f(Y )− EQ[f(Y )|X, Z = z, G = g])
qj(G = g)q(Z = z)
+ EQ[f(Y )|X, Z = z, G = g]− µzg(Q) , (7)
for z, g ∈ {0, 1}2. We will define µz(Q) := µz1(Q) − µz0(Q) and ϕz(Q) := ϕz1(Q) − ϕz0(Q)
for z = 0, 1. Standard calculations verify that ϕz(Q) is the efficient influence function for
µz(Q) by demonstrating that ϕz(Q) can be expressed as a pathwise derivative of µz(Q)
where Q is a parametric submodel of Q such that Q = Q=0 (Kennedy, 2016). ϕz(Q) is
said to be a pathwise derivative of µz(Q) if EQ[ϕz(Q)S] = ∂µz(Q)/∂|=0 where S is the
17
score function of the parametric submodel. Finally, let ϕ∗zg(Q) = ϕzg(Q) − EP [ϕzg(Q) |G]
and define ϕ∗z(Q) := ϕ∗z1(Q) − ϕ∗z0(Q). We can now state the consistency and asymptotic
normality result for τˆ .
Proposition 2 (Consistency and Asymptotic Normality). In addition to Assumptions 1 - 5,
suppose that the number of sites J is fixed, the Ij grow at the same rate as n, and the
maximizers β = [β(0),β(1)] exist. Also, suppose that ||β||∞ < M for pre-specified M < ∞.
Finally, let (X, Y ) be bounded and the terms in the linear parts of the GLMs in steps 1 and 2
of Algoritm 1 be bounded functions on compact subsets of {0, 1}2×Rd. Then, τˆ is consistent
and
√
n(τˆ − τ) convergence in distribution to a Gaussian with mean 0 and variance
σ2 = EP
[
µ1(P )
µ0(P )2
(ϕ∗0(P∞)(O)− Pϕ∗0(P∞)(O)} −
1
µ0(P )
{ϕ∗1(P∞)(O)− Pϕ∗1(P∞)(O)}
]2
.
When the prevalence of G does not vary between sites and the study is balanced, i.e.,
Ij = n/J for all j, then step 2 of Algorithm 1 can be skipped. Step 2 may also be skipped if
it is a single-site trial. Furthermore, if the working model for EP [f(Y ) |X,Z,G] is correctly
specified then σ2 achieves the semiparametric efficiency bound.
Proof. A sketch of the proof of Proposition 2 can be found in Appendix B.4 of the Supple-
mental Web Materials.
Remark 1. We remarked in §3.3.2 that Proposition 1 still holds under a weaker version of
Assumption 4 where the independence is conditional on baseline covariates X. Proposition
2 also holds under these weaker assumptions as long as either the working model for the
conditional expectation or the conditional assignment models for G and Z are correctly
specified.
Variance Estimator:
Notice that ϕ∗z is defined as a projection of ϕz into a lower dimensional subspace and will
thus have smaller variance. With that in mind, we can use ϕz(Pn) to construct a conservative
plug-in estimator of σ2. In Appendix B.4 of the Supplemental Web Materials we show that
Pn solves the EIF estimating equations, that is, Pnϕz(Pn)(O) = 0 for z = 0, 1. It follows
then that the plug-in estimator of the scale variance σ2 can be written simply as
n · v̂ar(τˆ) = 1
n
J∑
j=1
Ij∑
i=1
{
ϕ0(Pn)(Oij)
µ1(Pn)
µ1(Pn)2
− ϕ1(Pn)(Oij) 1
µ0(Pn)
}2
(8)
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With this variance estimator we can now use Proposition 2 to conduct inference on and
construct confidence intervals for τˆ .
Naive Estimator:
For simplicity, let’s assume that we have balanced sites, i.e., Ij = n/J for all j. Then,
had we assumed that all fevers with any parasitemia were malaria-attributable fevers, we
might considered the following naive estimator
τˆ0 = 1− Pnµˆ0(1, G,X)Pnµˆ0(0, G,X) . (9)
The naive estimator corresponds with standard estimates of VE with respect to a commonly
used secondary case definition of the presence of a fever (Y = 1) and any positive parasite
density (D > 0) (Olotu et al., 2013). We will see in the following section that the estimator
is systematically biased but can be combined with our MFD estimator τˆ to construct an
estimator that outperforms both estimators on their own.
3.5 Simulation Study: Comparison to Naive Identification Strategy
In this section we investigate the performance of our proposed MFD estimator τˆ and compare
it to that of the naive estimator τˆ0 that assume all fevers with any parasitemia are malaria
fevers. As in the previous section, we consider f(y) = 1Ty and thus τ is the proportion
reduction in expected number of malaria-attributable fevers. We consider a single-site RCT
J = 1 with equal sized vaccine and placebo arms and the prevalence of HbAS set to 20%
based on existing estimates of the prevalence in sub-Saharan Africa (Ter Kuile et al., 2003;
Elguero et al., 2015).
We simulate the number of malaria-attributable fevers and non-malaria fevers from nega-
tive binomial distributions in a single year of follow up for each individual. Evidence suggests
that the negative binomial distribution fits the empirical distribution of the number of clin-
ical malaria events an individual experiences well (Olotu et al., 2013). We can also see
from (1) that Y m and Y nm are negatively dependent – a fever cannot be both attributable
to malaria and have been present in the absence of malaria. To model this dependence
structure, we use a Gaussian copula with negative dependence parameter ρ = −0.1 (Genest
and Neslehová, 2007). The negative dependence is modest when fevers are rare but will be
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more pronounced in areas where fever risk is higher, e.g., villages with poor sanitation. We
suppose there is a single observed covariate X that enters the conditional mean function for
both 1TY m and 1TY nm and that there is unobserved heterogeneity in the conditional means
between individuals. The generating distributions were calibrated so that the average num-
ber of any-cause fevers is 1.5 per child-year. We also calibrated the generating distributions
to achieve different levels of case specificity, which we define formally below.
Two different sample sizes were chosen to assess how performance improved asymptot-
ically: 1000 subjects per trial arm, i.e., n = 2000, and 2500 subjects per trial arm, i.e.,
n = 5000. For n = 2000, we consider 5 × 2 × 2 different combinations of vaccine efficacy
τ ∈ {0.3, 0.4, 0.5, 0.6, 0.7}, protective efficacy of the Mendelian factor ν ∈ {0.3, 0.5}, and
specificities s ∈ {0.5, 0.8}. Formally, we define specificity s here as the expected number of
malaria-attributable fevers divided by the expected number of fever with any parasitemia
and of any cause under placebo,
s =
EP
[
1TY m(0, G)
]
EP [1TY (0, G)]
=
p(G = 1)µm01 + p(G = 0)µ
m
00
p(G = 1)µ01 + p(G = 0)µ00
. (10)
The specificity choices are motivated by Mabunda et al. (2009), which estimated the
specificity of standard case definitions using > 0 and > 2500 parasites per µl cutoffs for
children under five years of age to be roughly 50% and 80%, respectively. The strength
of the Mendelian factor was calibrated to the aforementioned estimates of the protective
efficacy of HbAS. We consider the same combinations for n = 5000 except only for the weaker
protective efficacy setting. The spillover efficacy η was assumed to be zero. Finally, we allow
for non-constant vaccine and Mendelian protective efficacy – both τi and νi are log-normally
distributed with mean τ and ν, respectively, and standard deviation approximately 0.05
giving coefficients of variation of about 8-17%. Rather than conferring complete protection
to a fraction of the vaccinated subjects, all vaccinated subjects receive partial protection.
This is consistent with evidence that RTS,S is a “leaky" vaccine, providing at least partial
protection to all recipients of the vaccine (Moorthy and Ballou, 2009). Each setting was
simulated Nsim = 5000 times. More details of the simulation settings can be found in
Appendix B.5 of the Supplemental Web Materials. R code to reproduce the simulation
results can be found in the Supplementary Materials.
We use Poisson regression for the initial working model estimate in Algorithm 1 and
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because J = 1, we skip step 2. The results of the simulation study are summarized in the
following two tables. In Table 2 we compare the absolute proportional bias and root mean
squared error (RMSE) of the τˆ (MFD) and τˆ0 (Naive). For n = 2000, the MFD estimator
has very good bias properties, with proportional bias less than 5% for most settings. The
RMSE increases for Mendelian genes that are less protective and as the specificity decreases.
The only area of poor bias performance is when the Mendelian gene is weakly protective
(ν = 0.3) and the specificity is low (0.5). However, although the estimator in this setting has
high variance the bias and power at τ = 0.7 are reasonably adequate. Like the presence of
small sample bias and high variance for weak instruments in instrumental variable analysis
(Imbens and Rosenbaum, 2005), the poor performance appears to be a small sample property
as the performance for the weak Mendelian gene, low specificity setting improves notably for
n = 5000.
The bias in the naive estimator only varies over the different specificity settings and does
not improve as the sample size grows. In fact, because there is no spillover efficacy, the
proportional absolute bias is equal to 1 − s. You can see from the table that the RMSE
is driven almost entirely by the bias component for the naive estimator and it actually
increases in absolute terms as the vaccine efficacy increases. These properties lead to very
poor coverage of confidence intervals derived from the naive estimator. That one should
expect efficacy estimates to be biased by as much as 20% when specificity is at the level
recommended by the WHO should be cause for concern.
Table 3 below compares the coverage of two-sided 95% confidence intervals and the power
against the two-sided alternative at 5% significance for the MFD and naive procedures. The
MFD confidence interval has correct or conservative coverage and decent power in even some
of the more unfavorable settings. Even in the small sample, weakly protective Mendelian
gene, and low specificity setting the power is not negligible at higher vaccine efficacies.
Because the naive estimator is systematically biased, the coverage properties are extremely
poor in all settings. The variance of the naive estimator tends to be far smaller than the
MFD estimator. This fact coupled with the systematic bias leads to high power and low
coverage across all settings.
Even in settings where the mean proportional bias is high, the MFD estimator appears
to have the desirable property of being median unbiased. Figure 3 demonstrates this for
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Table 2: Proportional absolute bias and root mean squared error (RMSE) of MFD and naive
estimators using Nsim = 5000 simulations.
Specificity = 0.8 Specificity = 0.5
Prop. |Bias| RMSE Prop. |Bias| RMSE
ν τ MFD Naive MFD Naive MFD Naive MFD Naive
n = 1000 (×2 )
0.50 0.30 0.03 0.20 0.15 0.07 0.12 0.50 0.29 0.15
0.40 0.02 0.20 0.14 0.08 0.07 0.50 0.27 0.20
0.50 0.02 0.20 0.12 0.10 0.05 0.50 0.25 0.25
0.60 0.02 0.20 0.11 0.12 0.04 0.50 0.24 0.30
0.70 0.01 0.20 0.10 0.14 0.02 0.50 0.22 0.35
0.30 0.30 0.12 0.20 0.36 0.07 0.59 0.50 5.47 0.15
0.40 0.11 0.20 0.30 0.09 0.32 0.50 4.54 0.20
0.50 0.08 0.20 0.29 0.10 0.21 0.50 5.80 0.25
0.60 0.06 0.20 0.24 0.12 0.18 0.50 4.61 0.30
0.70 0.03 0.20 0.21 0.14 0.11 0.50 1.69 0.35
n = 2500 (×2 )
0.30 0.30 0.06 0.20 0.18 0.06 0.18 0.50 0.37 0.15
0.40 0.04 0.20 0.17 0.08 0.13 0.50 0.34 0.20
0.50 0.02 0.20 0.14 0.10 0.08 0.50 0.30 0.25
0.60 0.02 0.20 0.13 0.12 0.06 0.50 0.29 0.30
0.70 0.01 0.20 0.12 0.14 0.04 0.50 0.27 0.35
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Table 3: Coverage of two-sided 95% confidence interval and power against two-sided alter-
native at 5% significance level of MFD and naive estimators using Nsim = 5000 simulations.
Specificity = 0.8 Specificity = 0.5
Coverage Power Coverage Power
ν τ MFD Naive MFD Naive MFD Naive MFD Naive
n = 1000 (×2 )
0.50 0.30 0.95 0.50 0.56 1.00 0.96 0.00 0.29 0.99
0.40 0.95 0.17 0.79 1.00 0.96 0.00 0.44 1.00
0.50 0.96 0.01 0.94 1.00 0.96 0.00 0.59 1.00
0.60 0.96 0.00 0.99 1.00 0.96 0.00 0.73 1.00
0.70 0.96 0.00 1.00 1.00 0.97 0.00 0.84 1.00
0.30 0.30 0.95 0.50 0.30 1.00 0.95 0.00 0.19 0.99
0.40 0.95 0.16 0.44 1.00 0.96 0.00 0.25 1.00
0.50 0.96 0.01 0.57 1.00 0.96 0.00 0.33 1.00
0.60 0.96 0.00 0.74 1.00 0.97 0.00 0.42 1.00
0.70 0.96 0.00 0.86 1.00 0.98 0.00 0.51 1.00
n = 2500 (×2 )
0.30 0.30 0.95 0.11 0.45 1.00 0.95 0.00 0.26 1.00
0.40 0.96 0.00 0.68 1.00 0.96 0.00 0.38 1.00
0.50 0.95 0.00 0.87 1.00 0.96 0.00 0.52 1.00
0.60 0.96 0.00 0.96 1.00 0.97 0.00 0.66 1.00
0.70 0.96 0.00 0.99 1.00 0.97 0.00 0.77 1.00
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τ = 0.3, 0.5, and 0.7 in all six settings detailed in Tables 2 and 3. The dashed lines indicates
the true value of τ , the boxes represents the IQRs, and the whiskers indicate the 5% and 95%
quantiles of the simulated estimates. The diamonds indicate the means and the vertical solid
lines the medians. The worsening performance of the MFD as the Mendelian gene weakens
is clear (settings 2 vs. 1, 4 vs. 3, and 6 vs. 5) as is the improvement in the weak Mendelian
gene settings as the sample size grows (settings 5 vs. 3 and 6 vs. 4). The naive estimates
have much lower variance but are systematically mean and median biased downward. The
MFD estimates are also mean biased downward. Although the estimator is asymptotically
normal, the ratio of means that are jointly asymptotically normal may have a peculiar non-
normal form in finite samples which may explain this particular pattern of bias (Marsaglia
et al., 2006).
0.3 0.5 0.7
−1.0 −0.5 0.0 0.5 1.0 −0.5 0.0 0.5 1.0 0.0 0.5 1.0
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Figure 3: Distributions of simulated MFD estimator τˆ and naive estimator τˆ0 over several
settings and τ = 0.3, 0.5, 0.7. Setting 1: strong factor (ν = 0.5), high specificity (s = 0.8);
setting 2: strong factor, low specificity (s = 0.5); settings 3 and 5: weak factor (ν =
0.3), high specificity; settings 4 and 6: weak factor, low specificity. Dashed lines indicate
true efficacy, boxes indicate IQRs, whiskers are 5% and 95% quantiles, diamonds are mean
estimate, and vertical solid lines are median estimates.
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3.6 Improved Estimators: Leveraging the Identifying Assumptions
3.6.1 A Simple Correction to the Naive Estimator
The observation that the proportional absolute bias of τˆ0 is equal to 1 − s in Table 2 for
all settings comes from the fact that, when the sample sizes are balanced across sites, an
immediate application of Theorem 1 of Rosenblum and van der Laan (2010) yields that τˆ0
is a consistent estimator of sτ + (1− s)η. When samples are small or the Mendelian gene is
only weakly protective, we observed that the MFD estimator will be less powerful and may
suffer from small sample bias. In such settings, the asymptotic limit of τˆ0 suggests a simple
correction to the naive estimator: dividing by s. Call this the s-corrected estimator, which
is consistent for τ when η = 0 and s is known or consistently estimated itself. If instead we
only have a 1− β confidence interval for s, Cβ, then we can still construct a valid confidence
interval for τ using the s-corrected estimator. Let CIs,α+β be a 1−α− β confidence interval
for τ constructed using the s-corrected estimator and define the s-corrected 1−α confidence
interval CIcorr,α =
⋃
s∈Cβ CIs,α+β. Berger and Boos (1994) show that one can construct
valid p-values by maximizing a non-pivotal p-value over the confidence set of a nuisance
parameter. This result is easily inverted, providing a procedure to construct valid confidence
intervals from which it follows that CIcorr,α will have the correct (conservative) coverage for
τ . However, as we mentioned earlier in §3.2.1, estimating and conducting inference about s
is challenging. However, we can still make use of the naive estimator even when we do not
know s.
3.6.2 The Best of Both Worlds? Combining MFD and Naive Estimators
The naive estimator and the MFD estimator have complementary strengths and different
weaknesses – τˆ0 tends to be more efficient but is asymptotically biased and τˆ is consistent but
has higher variance and requires larger sample sizes. The naive estimator also has the nice
feature of being a consistent lower bound of τ as long as η ≤ τ – it is very plausible that a
well designed vaccine will have a higher vaccine efficacy than spillover efficacy. Additionally,
we have the logical constraint that τ ≤ 1 since a treatment efficacy greater than one would
imply that it would be possible to have a negative number of malaria-attributable fevers,
a scenario eliminated by the assumption that Y (d, u) is monotonically increasing in d for
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all levels u. The following proposition constructs an estimator that uses these upper and
lower bounds to improve the performance of τˆ in difficult settings, e.g., small samples, weak
Mendelian factor, and low specificity.
Proposition 3 (Bounded Estimator). Suppose that η ≤ τ . Let τˆ0 be the naive estimator and
let
Lα = τˆ − Φ(1− α)v̂ar(τˆ)1/2
L0,α = τˆ0 − Φ(1− α)v̂ar(τˆ0)1/2 .
Define the upper confidence bounds Uα and U0,α similarly. Then (i)
τˆbnd = min [1,max {τˆ , L0,α˜}] (11)
is consistent for τ when α˜ is bounded away from 1; and (ii), for 0 ≤ α0 ≤ α/2
CIbnd,α =
[
max{Lα/2−α0 , L0,α0},min
{
1, Uα/2
}]
(12)
is an asymptotically valid 1− α confidence interval for τ .
Proof. The proof of Proposition 3 can be found in Appendix B.3 of the Supplemental Web
Materials.
Because the naive estimator has much smaller variance than the MFD estimator, one
will likely choose α0 and α˜ to be much smaller than α. In general, it makes sense to choose
α˜ = α0 to ensure that τˆbnd ∈ CIbnd,α.
The lower bound used to construct τˆbnd acts like a high probability, stochastic lower bound
to τ while 1 is an exact upper bound. When the Mendelian gene is weak, the denominator in
τˆ can sometimes be very close to zero, leading to unreliable estimates of vaccine efficacy. The
bounded estimator is designed to mitigate the effect of these cases while keeping the median
unbiasedness of τˆ intact. Figure 4, illustrates how this plays out in a the setting where the τˆ
performs poorly with n = 2000, a weak Mendelian factor, low specificity, and τ = 0.5. The
figure shows the estimated densities and means of the naive estimator (blue, dash), MFD
estimator (gray, dot), and bounded estimator (green, dot-dash) over 5000 simulations. The
true vaccine efficacy is indicated by the black solid line. As expected, τˆ is much more variable
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and less biased than τˆ0, but still materially biased in this setting. The bounded estimator
τˆbnd is nearly mean unbiased. You can see how it achieves this by “clumping" unreliable
MFD estimates near the stochastic lower bound and the exact upper bound.
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Figure 4: Densities and means of naive estimator (blue, dash) MFD estimator (gray, dot),
and bounded estimator (green, dot-dash); True vaccine efficacy (black, solid). For the setting
with n = 1000(×2), τ = 0.5, ν = 0.3, spec. = 0.5, and α˜ = 0.001
We also assess how well τˆbnd performs in the same setting as in Figure 4 but with an
even smaller sample size (n = 1000). Using α = 0.05, α0 = 0.001, and α˜ = 0.001, we
find that τˆbnd has substantially improved bias and RMSE while CIbnd,α has very favorable
power while maintaining the correct (conservative) coverage. In Figure 5, we compare the
absolute proportional bias (left panel) and RMSE (right panel) of the three estimators.
Absolute proportional bias and RMSE values larger than 1 are not shown. The bounded
estimator uniformly outperforms both the MFD and naive estimators in terms of bias and
has performance comparable to that of the MFD estimator estimated on a sample five times
as large (n = 5000) for τ = 0.5, 0.6, and 0.7. The RMSE of τˆbnd shows large improvements
over the τˆ and is comparable to the RMSE of τˆ estimated in the same setting on a sample
size of n = 5000 for all values of τ considered.
The power and coverage properties of CIbnd,α give the clearest picture of how the comple-
mentary strengths of the MFD and naive procedures are retained by the bounded procedure.
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Figure 5: Absolute proportional bias (left panel) and RMSE (right panel) for MFD, naive,
and bounded estimators with sample size n = 1000 and Nsim = 5000 simulations. For
bias and RMSE values above 1, only a maximum of 1 is shown. The actual absolute
proportional bias values for the MFD estimator are 2.21 and 1.56 for τ = 0.3 and 0.4,
respectively. The actual RMSE values for the MFD estimator from left to right are
18.58, 67.90, 32.29, 8.42, and 6.75.
In the left panel of Figure 6, we see that CIbnd,0.05 has only marginally more conservative
coverage than the MFD confidence interval [L0.025, U0.025] (right panel) while retaining the
favorable power properties of the naive confidence interval [L0,0.025, U0,0.025] (left panel). The
dashed line in the right panel indicates 95% coverage.
Importantly, the superior performance of the bounded estimator in this particular setting
does not appear to come at the expense of performance in the settings where τˆ generally
does well, improving on the τˆ in almost all settings investigated in the simulation study.
4 Discussion
The strategy that we’ve developed for identification and estimation of malaria vaccine efficacy
does not rely on the explicit definition of an inexact, but observable case definition. In short,
we propose separating the approach to identifying VE into two distinct steps: first, define
a gold-standard case that may be unobservable and then, identify VE using a strategy
that doesn’t require overt observation of these gold-standard cases. Our gold-standard case
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Figure 6: Power against two-sided alternative at 5% significance (left panel) and coverage of
95% confidence interval (right panel) for MFD, naive, and bounded estimators with sample
size n = 1000 and Nsim = 5000 simulations. The dashed black line in the right panel
indicates 95% coverage.
definition is one that is 100% specific and sensitive. It is precisely defined using a potential
outcome framework. As we’ve noted, these cases are not distinguishable from observed
data alone. Regardless, we demonstrate that with Mendelian factorial design we are able
to leverage genetic variation in an analogous fashion to Mendelian randomization studies to
identify VE with respect to this exact, but unobservable, case definition.
In observational studies, evidence factors are defined as several approximately indepen-
dent tests of the same hypothesis, each of which depend on different assumptions about bias
from non-random treatment assignment (Rosenbaum, 2011). In the presence of bias, these
tests can be thought of as independent pieces of evidence in that the violation of assumptions
underlying one test does not imply the other tests are similarly biased. Like an evidence fac-
tor, the MFD estimate can provide an additional piece of evidence in vaccine efficacy studies
that relies on a different set of assumptions than the methods currently in use. For instance,
the naive estimator assumes all fevers with any parasitemia are malaria-attributable, cor-
responding to a commonly used secondary case definition. Although not independent like
true evidence factors, we demonstrated that the naive estimator and the MFD estimator
can be combined to construct a bounded estimator that outperforms both estimators when
used on their own. In particular, the bounded estimator provides significant improvements
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when the Mendelian gene is only weakly protective, a challenging setting similar to the weak
instrument setting in IV studies.
There is evidence that HbAS is to moderately protective against uncomplicated malaria
and highly protective against severe malaria illness suggesting that MFD may be particularly
useful for estimating VE against severe malaria, whose symptoms are not specific and overlap
significantly with symptoms of other severe childhood comorbidities (Bejon et al., 2007).
The performance of the combined estimator across a range of simulation settings with
sample sizes that are similar to those found in phase II and III clinical trials is promising.
The results suggests that, if feasible, it would be prudent to begin collecting subject data
on inherited hemoglobinopathies and other genetic traits that provide protection against
clinical malaria, such as the sickle cell trait. Estimating the efficacy of prevention strategies
that target transmission directly, such as a malaria transmission-blocking vaccine (Wu et al.,
2015) and insecticide-treated bed nets (Ter Kuile et al., 2003), are feasible under the MFD
framework developed in this paper. The assumption of no interference will likely fail but
weakening Assumption 3 to allow for partial interference (Hudgens and Halloran, 2008), e.g.,
interference within but not between villages or sites, is plausible. Cluster randomized trial
designs would allow for identification of natural definitions of treatment efficacy that are
functions of the fraction of subjects who receive treatment (Athey et al., 2018). The study
of erythrocytic vaccines in the MFD framework may be more challenging, as the assumption
that protective hemoglobinopathies and these blood-stage vaccines don’t interact is tenuous
at best. With more than thirty vaccines currently under development, both pre-erythrocytic
and those targeting different stages of the disease cycle, the methods described in this paper
have the potential to improve the reliability of vaccine efficacy estimates for a number of
forthcoming trials (Mahmoudi and Keshavarz, 2017).
Many interesting research directions related to Mendelian factorial design remain. We
mention a few in closing. Developing MFD methods using only aggregate site-level data
on HbAS prevalence is one such direction. This might allow for MFD-based meta-analyses
of past trial results in which hemoglobinopathy data were not collected if, (1) accurate
prevalence data could be collected ex post and (2) the prevalence varied sufficiently between
studies. There is evidence that there are a number of other genetic traits that confer protec-
tion against malaria (Ndila et al., 2018). When there are several potential valid Mendelian
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factors, we may again find inspiration from MR and other IV methods. It would be beneficial
to develop falsification tests of the validity of potential Mendelian factors akin to tests for
over-identifying restrictions such as the Sargan-Hansen test in IV regression (Hansen, 1982).
As it has been demonstrated in MR, using many ostensible Mendelian factors where some
are invalid may have the potential to improve the robustness of MFD analysis (Kang et al.,
2016). Finally, the application of MFD to the study of vaccines against other childhood dis-
eases that have unspecific symptoms and no gold-standard case definition, such as pediatric
tuberculosis (Beneri et al., 2016), could prove fruitful if plausible mendelian factors can be
identified.
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Supplemental Web Materials for Estimating Malaria
Vaccine Efficacy in the Absence of a Gold Standard
Case Definition: Mendelian Factorial Design
A Time-to-First Malaria Fever: Mendelian Factorial De-
sign Under The Proportional Hazards Assumption
The World Health Organization (WHO) recommends that the primary endpoint in pivotal
Phase III trials assessing the efficacy of malaria vaccines be the time-to-first malaria fever and
that the efficacy be measured as one minus the hazard ratio returned by a Cox proportional
hazard regression (Moorthy et al., 2007). In this section we use our potential outcome
framework to precisely define vaccine efficacy in time-to-first malaria fever studies and show
how it can be identified using MFD and estimated using data on time-to-first fever of any
cause.
A.1 Parameter Identification and Estimation under Modeling As-
sumptions
In this section we can think about our clinical outcomes as stochastic processes indexed by
t, Y := {Yt}t≥0. This allows us to consider quantities like the time to first fever, T = min{t :
Yt = 1}.
If we follow the WHO recommendation above in the context of the potential outcome
framework developed in §3.2, a natural quantity to study in a time-to-event analysis of vac-
cine efficacy is the hazard rate of malaria-attributable fevers, i.e., the instantaneous risk
of developing a malaria-attributable fever at time t conditional on being free of malaria-
attributable fevers up to time t. The risk set used in this hazard function includes individuals
who have experienced non-malaria fevers prior to time t. This is analogous to a subdistri-
bution hazard in the competing risks literature where non-malaria fevers can be viewed as a
competing risk (Fine and Gray, 1999). Unfortunately, when Y m is not observable, vaccine
efficacy based on a hazard ratio using the definition of malaria-attributable fever in (1) is not
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identifiable using MFD. This is due to the fact that on the hazard ratio scale, Assumption
1 (additivity) does not hold when Y m and Y nm are dependent – recall, if Y nmt equals 1 then
Y mt must equal 0 but is otherwise free to take values in {0, 1}. Only under independence
(or independence conditional on X) can we additively decompose the hazard of developing a
fever of any cause into the hazard of developing a malaria-attributable fever and the hazard
of developing a non-malaria fever. That said, under a few additional assumptions we can
still identify vaccine efficacy in terms of the hazard rate for malaria-attributable fevers in the
absence of non-malaria infections. This hazard is analogous to a cause-specific hazard in the
competing risks literature when competing risks can be considered conditionally independent
(Hsu et al., 2017).
A.1.1 Malaria-attributable Fevers in the Absence of Competing Infections
If we assume that there is no combined effect of malaria and non-malaria infections on
fevers (Assumption 2(iii) of Lee and Small (2018)), then we can provide an alternative
decomposition of Y to the decomposition presented in (1):
Y (D(z, g), U(z)) = Y (D(z, g), 0) ∨ Y (0, U(z)) , (13)
where Y (D(z, g), 0) are malaria-attributable fevers in the absence of non-malaria infec-
tions, Y (0, U(z)) are non-malaria fevers in the absence of malaria infections, and ∨ is a
pairwise maximum. For stochastic processes, A ∨ B = {max(At, Bt)}t≥0. We will refer to
Y (D(z, g), 0) and Y (0, U(z)) as isolated malaria fevers and isolated non-malaria fevers. If
X sufficiently captures shared risk factors for malaria and non-malaria infections, then it is
plausible that D(z, g) ⊥⊥ U(z) | X and thus Y (D(z, g), 0) ⊥⊥ Y (0, U(z)) | X for all z, g.
One might wonder if isolated malaria fevers are the endpoint of greatest interest. Perhaps
malaria-attributable fevers as defined in (1) are more representative of the real-world burden
of malaria infections. Regardless, one could argue that the standard case definition of clinical
malaria, e.g., Y = 1 andD > 2500 parasites per µl, is an approximation of an isolated malaria
fever. This argument has two parts: (1) the fixed threshold suggests that the standard case
definition does not consider the possibility of combined effects of malaria and non-malaria
fevers; and (2) the standard case definition does not consider whether a non-malaria fever
would have occurred had there been no malaria infection. The approximation is rough,
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however, because while the definition of isolated malaria fever allows for individual-specific
pyrogenic thresholds, the standard case definition does not.
A.1.2 Identifying Vaccine Efficacy
We can now define the potential time to first isolated malaria fever as Tm(z, g) = min{t :
Yt(D(z, g), 0) = 1} and the potential time to first isolated non-malaria fever as T nm(z, g) =
min{t : Yt(0, U(z)) = 1}. We can write the conditional hazard functions for Tm(z, g) and
T nm(z, g) as
λkzg(t |X) = lim
∆→0+
P
(
T k(z, g) ∈ [t, t+ ∆ )|T k(z, g) ≥ t, X) /∆ (14)
for k = m,nm and all z, g. We drop the superscript k to indicate the conditional hazard
function for the a fever of any cause and define
T (z, g) = min{t : Yt(z, g) = 1} = min{Tm, T nm} .
Assumption 6 (Proportional Hazards). λkzg(t |X), k = m,nm follow a Cox proportional
hazard model with baseline hazard functions λk(t), k = m,nm. That is,
(i) λmzg(t |X) = λm(t) exp{log κ+ log(1− τ)z + log(1− ν)g + βTmX} , and
(ii) λnmzg (t |X) = λnm(t) exp{log φ+ log(1− η)z + βTnmX}
where ν > 0.
In equation (i) above, vaccine efficacy τ is equal to one minus the hazard ratio of isolated
malaria fever under vaccination versus placebo. In (ii), η can again be thought of as a
“spillover efficacy” term. Note that Assumptions 2 and 5 are satisfied under these modeling
assumptions.
Assumption 7 (Conditionally Independent First Fever Processes). The time to first isolated
malaria fever and time to first isolated non-malaria fever are conditionally independent. That
is,
Tm(z, g) ⊥⊥ T nm(z) | X for (z, g) ∈ {0, 1}2
Because Tm(z, g) depends only on Y (D(z, g), 0) and T nm(z, g) depends only on Y (0, U(z)),
Assumption 7 is satisfied when Y (D(z, g), 0) ⊥⊥ Y (0, U(z)) | X for all z, g. We previously
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argued that this condition is plausible when X sufficiently describes shared risk factors for
malaria and non-malaria infections.
Assumption 8 (Shared Conditional Baseline Hazard Function). Time-to-first isolated malaria
fever and time to first isolated non-malaria fever have a shared baseline hazard function
conditional on X. That is, λ(t) := λm(t) = λnm(t) for all t ≥ 0 and β := βm = βnm.
Under these additional assumptions, we can use an MFD strategy to identify τ in time-
to-first fever studies.
Proposition 4 (Identification of τ). Suppose that Assumptions 6 - 8 hold. Then the hazard
function for T (z, g) can be written as
λzg(t |X) = λ(t) exp{α + ωz + γg + λz × g + βTX} . (15)
Furthermore, under Assumptions 3 and 4, τ is identified from the observed data O as
τ = 1− exp{ω + γ + λ} − exp{ω}
exp{γ} − 1 . (16)
Proof. The proof of Proposition 4 can be found in Appendix B.2
Remark 2. The conditions of Proposition 4 lead to an additivity property of the conditional
hazard functions that is analogous to Assumption 1. This additivity can be seen in the first
equality of (26).
Remark 3. A weaker version of the randomization / “as-if” randomized condition imposed by
Assumption 4 would suffice to identify τ . Namely, that Z,G are independent of all potential
outcomes conditional on X.
A.1.3 Estimation and Inference via the Delta Method
The parameters in (15) can be estimated consistently via maximum partial likelihood esti-
mation (Cox, 1975) with the R function coxph implemented in the survival package. These
estimates (ωˆ, γˆ, λˆ) are asymptotically normal with the limiting distribution
√
n


ωˆ
γˆ
λˆ
−

ω
γ
λ

 D−→ N


0
0
0
 , I([ω, γ, λT ])−1
 , (17)
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where I([ω, γ, λT ])−1 is the inverse of the partial likelihood-based information matrix. Apply-
ing the continuous mapping theorem to (16) yields the following consistent MFD estimator
of τ ,
τˆ = 1− exp{ωˆ + γˆ + λˆ} − exp{ωˆ}
exp{γˆ} − 1 . (18)
Applying the delta method to (17) and (18) and noting that Iˆ([ωˆ, γˆ, λˆT ])−1/n, the average
sample information, is consistent for I([ω, γ, λT ])−1 gives us an approximate distribution for
τˆ for large enough samples,
τˆ ∼˙ N
(
τ,∂τˆ T Iˆ([ωˆ, γˆ, λˆT ])−1 ∂τˆ
)
, (19)
where ∂τˆ = [∂τˆ/∂ωˆ, ∂τˆ/∂γˆ, ∂τˆ/∂λˆ]T . We can use this approximate distribution to conduct
inference on τ .
An analogous bounded estimator and confidence interval to those described in Proposition
3 can be constructed using the naive estimator 1− exp{ωˆ}. It can easily be shown that this
estimator is consistent for a convex combination of τ and η and is thus is a consistent
estimator for a lower bound of τ as long as η ≤ τ .
A.2 Causal Identification: Selection Bias and Frailty
Even if these strong modeling assumption assumptions hold, τ defined in §A.1 does not have a
straightforward causal interpretation. Several authors have discussed in depth the subtleties
and common misconceptions of interpreting hazard ratios as a causal quantity (Hernán,
2010; Aalen et al., 2015; Martinussen et al., 2018). We observe one of these subtleties when
examining the definition of τ given in Assumption 6(i),
τ = 1− lim∆→0+ P(T
m(1, g) ∈ [t, t+ ∆ )|Tm(1, g) ≥ t, X)
lim∆→0+ P(Tm(0, g) ∈ [t, t+ ∆ )|Tm(0, g) ≥ t, X)
. (20)
These authors point out that the hazard functions in the numerator and the denominator
of (20) condition on different sets of subjects for t > t(1) = minij,g,z Tmij (g, z). The causal
contrast is thus some combination of treatment efficacy and a selection effect. Initially,
randomized assignment of Z and “as-if" randomization of G ensure that the units in each
combination of trial arm and HbAS status are comparable on average. However, conditioning
on the study subjects at risk of their first isolated malaria fever at time t > t(1), i.e.,
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Tm(z, g) ≥ t, has the potential to introduce selection bias. For instance, suppose that
baseline susceptibility to malaria is heterogeneous even after conditioning onX. If Z provides
protection against developing an isolated malaria fever, we might find that the children with
high susceptibility to malaria in the control arm are more likely to develop fevers than
similar children in the treatment arm. Consequently, as time passes, the children at risk in
the control arm will be less susceptible on average to fever than those in the treatment arm,
absent treatment. The comparability of the subjects in each combination of z, g ∈ {0, 1}2
ensured by Assumption 4 at the beginning of the study is not guaranteed as the follow-up
progresses.
When malaria-attributable fever is rare or when the follow-up time is short, the selection
effect may be less consequential (Aalen et al., 2015). If X does not sufficiently capture het-
erogenous susceptibility to isolated malaria fever, modeling subject-level frailty can further
alleviate the selection bias of estimates of τ (Wienke, 2010). Frailty can be introduced as a
multiplicative random effect,
λmzg(t |X) = λ(t)W exp{logα + log(1− τ)z + log(1− ν)g + βTX} ,
λnmzg (t |X) = λ(t)W exp{log φ+ log(1− η)z + βTX} (21)
where W is a random, subject-level frailty shared by both malaria and non-malaria fever
hazard functions. Proposition 4 extends immediately to the frailty model implied by (21)
where, in addition to X, the hazard ratio is conditional on W . Estimation can be carried
out via the Expectation-Maximization algorithm (Klein, 1992) or penalized partial maximum
likelihood methods (Therneau et al., 2003).
Alternatively, frailty models can be used to conduct a sensitivity analysis of Cox regression-
based estimates of τ to selection bias (Stensrud et al., 2017). In general, however, modeling
frailty usually requires parametric assumptions about W , for example, that it comes from
the family of power variance function distributions (Wienke, 2010).
Although τ itself has a subtle and potentially awkward causal interpretation, simple
functions of τ have been shown to have more natural causal interpretations. For example,
1/(2− τ) is the probabilistic index, which is defined as the probability that Tm(1, g) for one
individual is longer than Tm(0, g) for another individual with comparable baseline covariates
(and frailty) (De Neve and Gerds, 2019).
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Importantly, all the causal interpretations discussed in this section require the correct
identification of the parameter τ established in Proposition 4.
B Technical Appendices
B.1 Proof of Proposition 1
In this Appendix we give a proof of the general identification result in Proposition 1.
Proof of Proposition 1. By consistency and Assumption 3 we have that
EP [f(Y )|X,Z = z,G = g] = EP [f(Y (z, g))|X,Z = z,G = g] (22)
for all z, g. Assumption 4 ensures that PX|Z,G = PX and PY (z,g)|Z,G = PY (z,g). Hence,
EX [EP [f{Y (z, g)}|X,Z = z,G = g]] = EX|Z=z,G=g[EP [f{Y (z, g)}|X,Z = z,G = g]]
= EP [f{Y (z, g)}|Z = z,G = g]
= EP [f{Y (z, g)}]
= µzg(P ) . (23)
Applying Assumption 1, the right hand side of (2) becomes
1− (µ
m
11(P )− µm10(P )) + (µnm11 (P )− µnm10 (P ))
(µm01(P )− µm00(P )) + (µnm01 (P )− µnm00 (P ))
. (24)
Because G is a valid Mendelian factor (Assumption 5(ii)) we have that µnmz1 (P )−µnmz0 (P ) = 0
for z = 0, 1, further simplifying (24) to
1− (µ
m
11(P )− µm10(P ))
(µm01(P )− µm00(P ))
.
Finally, we have that
1− (µ
m
11(P )− µm10(P ))
(µm01(P )− µm00(P ))
= 1− −νµ
m
10(P )
−νµm00(P )
by Assumption 2 and Definition 1(ii)
= 1− µ
m
10(P )
µm00(P )
= τ by Definition 1(i) .
Assumption 5(i) ensures that the right hand side of the first equality is well-defined.
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B.2 Proof of Proposition 3
We give a short proof of the asymptotic unbiasedness of τˆbnd and the asymptotical validity
of CIbnd,α as a 1− α confidence interval for τ .
Proof of Proposition 3. We give a proof for when the sample sizes are balanced across sites.
When this is the case, we skip step 2 of Algorithm 1 and use µˆ0 to construct τˆ0. Treating G
as an element of X, the consistency of τˆ0 for sτ+(1−s)η and its asymptotic linearity follows
almost immediately from Theorem 1 of Rosenblum and van der Laan (2010). When η < τ ,
the theorem implies that τˆ0 is consistent for some τ ′ < τ . Because τ ≤ 1 by definition, the
continuous mapping theorem implies that τˆbnd is consistent for min[1,max{τ ′, τ}] = τ . The
lower bound of CIbnd,α is constructed by taking the intersection of a lower one-sided confidence
interval for τ with coverage 1 − α/2 + α0 and a lower one-sided confidence interval for τ ′
with coverage 1− α0. Because τ ′ < τ , this second confidence interval is also asymptotically
valid for τ . If α0 is chosen a priori, then the intersection is an asymptotically valid 1− α/2
lower one-sided interval for τ (Neuwald and Green, 1994). The upper confidence bound is
constructed by taking the intersection of a 1 − α/2 upper one-sided confidence interval for
τ and (−∞, 1]. Since τ ≤ 1 the resulting interval is an asymptotically valid 1 − α/2 upper
confidence-interval for τ . The intersection of the resultant upper and lower 1 − α/2 one-
sided confidence intervals yields an asymptotically valid two-sided confidence interval with
coverage 1− α.
B.3 Proof of Proposition 4
In this Appendix we provide a proof of the parameter identification result for the hazard
ratio under the proportional hazards assumption.
Proof of Proposition 4. Let Λzg(t |X) =
∫ t
−∞ λzg(t |X) dt be the cumulative hazard func-
tion for Y . Define Λkzg(t |X), k = m,nm similarly. The survival function Szg(t |X =
P(T (z, g) > t |X) can be expressed as Szg(t |X) = exp{−Λzg(t |X)} and the probability
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density of Y as fzg(t |X) = λzg(t |X)Szg(t |X). We can express fzg(t |X) as
fzg(t |X) = ∂
∂ t
Fzg(t |X)
=
∂
∂ t
{
1− Snmzg (t |X)Smzg(t |X)
}
by Assumption 7
= fmzg(t |X)Snmzg (t |X) + fnmzg (t |X)Smzg(t |X)
= {λmzg(t |X) + λnmzg (t |X)}Snmzg (t |X)Smzg(t |X)
= {λmzg(t |X) + λnmzg (t |X)} × exp
{
−
∫ t
−∞
λmzg(t |X) + λnmzg (t |X) dt
}
. (25)
From (25) and Assumptions 6 and 8, we have that the hazard function for Y is
λzg(t |X) = λmzg(t |X) + λnmzg (t |X)
= λ(t) exp{βTX} (κ(1− τ)z(1− ν)g + (1− η)z)
= λ(t) exp{α + ωz + γg + λz × g + βTX} , (26)
Proving the first part of the proposition. To prove the second part of the proposition we first
observe that the last equality above in (26) is simply a reparameterization – when z and g
are binary, κ(1− τ)z(1− ν)g + φ(1− η)z and exp{α+ ωz + γg + λz × g} can each take four
distinct values. The reparameterization yields a system of four equations,
exp{α} = κ+ φ (27)
exp{α + ω} = κ(1− τ) + φ(1− η) (28)
exp{α + γ} = κ(1− ν) (29)
exp{α + ω + γ + λ} = κ(1− τ)(1− ν) + φ(1− η) . (30)
Subtracting (28) from (30) and (27) from (29), then dividing the former by the latter yields
1− τ = exp{ω + γ + λ} − exp{ω}
exp{γ} − 1 . (31)
Under Assumptions 3 and 4 we have that λzg(t |X) can be identified by the observed data
O:
λzg(t |X) = lim
∆→0+
P(T (z, g) ∈ [t, t+ ∆)|T (z, g) ≥ t, X) /∆
= lim
∆→0+
P(T ∈ [t, t+ ∆)|T ≥ t, X, Z = z, G = g) /∆ . (32)
Applying (26), we have that α, ω, γ, λ are identifiable and thus τ can be identified by the
observed data using (31).
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B.4 Proof (Sketch) of Proposition 2
In this section we sketch a proof of Proposition 2 by showing that µzg(Pn) is consistent for
µzg(P ) and asymptotically linear, that is,
µzg(Pn)− µzg(P ) = (Pn − P)ϕ∗zg(P∞) + oP
(
1/
√
N
)
. (33)
for all z, g. Theorem 1 of Rosenblum and van der Laan (2010) checks a number of
technical conditions to verify that Theorem 1 of van der Laan and Rubin (2006) can be
applied. A particularly important condition is that the µzg(P ) are linear. This does not
hold in the setting when the prevalence of G in each site is not known a priori. Hence, a
straightforward application of the theorem is not appropriate. However, if certain weaker
conditions hold, then the important parts of Theorem 1 of van der Laan and Rubin (2006)
still apply. We first show that we can write
µzg(Pn)− µzg(P ) = (Pn − P)ϕ∗zg(Pn) . (34)
If ϕ∗zg(Pn) is Donsker then by the second part of Theorem 1 of van der Laan and Rubin
(2006), we have that µzg(Pn) is
√
n-consistent for µzg(P ). Then, if P{ϕ∗zgPn−ϕ∗zg(P∞)}2 → 0
in probability as n → ∞ the third part of Theorem 1 of van der Laan and Rubin (2006)
implies that µzg(Pn) is asymptotically linear with form (33). Consistency of µzg(Pn) and
Assumptions 1 - 5 imply that the plugin estimator τˆ is consistent for τ . Finally, we apply
the delta method to derive the asymptotic variance σ2 of
√
n(τˆ − τ). It follows from the last
part of Theorem 1 of van der Laan and Rubin (2006) that σ2 achieves the semiparametric
efficiency bound if the working model for the conditional expectation of f(Y ) is correctly
specified. In what follows, when taking expectations of functionals of Pn we treat these
functionals as fixed.
Verifying (34):
Given the choice of the terms included in the linear part of the GLM estimate µˆ1 in
Algorithm 1, the score equations that µˆ1 solve imply that
Pn
{
1(Z = z)1(G = g)
p(Z = z)pj,n(G = g)
(f(Y )− µˆ1(z, g,X))
}
= 0 for all z, g ∈ {0, 1}2 . (35)
The choice of the weighting w = n/Ij when estimating µˆ1 is required since Pn does not equally
weight observations unless the size of each site is the same. Also note, that by definition,
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Pnµˆ1(z, g,X) = µzg(Pn). Taken together, we have that Pnϕzg(Pn) = 0 for all z, g ∈ {0, 1}2.
By iterated expectations, we have that
Pϕ∗zg(Pn) = Pϕzg(Pn)− P {EP [ϕzg(Pn) |G]} = Pϕzg(Pn)− Pϕzg(Pn) = 0 . (36)
All that remains to be shown is that −Pn {EP [ϕzg(Pn) |G]} = µzg(Pn)−µzg(P ). We start
by evaluating EP [ϕzg(Pn) |G]:
EP [ϕzg(Pn) |G] = EP
[
1(Z = z)1(G = g) {f(Y )− µˆ1(z, g,X)}
pj,n(G = g)p(Z = z)
∣∣∣G]
+ EP [µˆ1(z, g,X)− µzg(Pn) |G]
=
1(G = g)
pj,n(G = g)
(µzg(P )− EP [µˆ1(z, g,X) |G])
+ EP [µˆ1(z, g,X) |G]− µzg(Pn) . (37)
The second equality follows from an application of iterated expectations, Assumption 4, and
the fact that µzg(Pn) and µˆ1 are treated as fixed when taking expectations. Taking the
empirical expectation Pn we get
Pn {EP [ϕzg(Pn) |G]} = Pn
{
1(G = g)
pj,n(G = g)
(µzg(P )− EP [µˆ1(z, g,X) |G])
}
+ Pn {EP [µˆ1(z, g,X) |G]− µzg(Pn)}
= µzg(P )− EP [µˆ1(z, g,X) |G = g]
+ Pn {EP [µˆ1(z, g,X) |G]} − µzg(Pn)
= µzg(P )− EP [µˆ1(z, g,X)] + EP [µˆ1(z, g,X)]− µzg(Pn)
= −(µzg(Pn)− µzg(P )) . (38)
The second to last equality comes from the fact that X ⊥⊥ G by Assumption 4. This is our
desired result and (34) now follows.
Checking that ϕ∗zg(Pn) is Donsker:
This is analogous to condition (iv) in the proof of Theorem 1 in Rosenblum and van der
Laan (2010). We make the same assumptions of boundedness on β and on the terms in
the linear part of the generalized linear models in steps 1 and 2 of Algorithm 1. Under the
additional assumption that 0 < δ ≤ pj(G = g) for all g = 0, 1 and j = 1, . . . , J , a nearly
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identical verification that ϕ∗zg(Pn) is Donsker follows. Hence, µzg(Pn) are
√
n-consistent for
all z, g ∈ {0, 1}12.
Verifying that P{ϕ∗zg(Pn)− ϕ∗zg(P∞)}2 P→ 0:
The steps to verify that P{ϕ∗zg(Pn) − ϕ∗zg(P∞)}2 → 0 in probability are very similar to
the verification of condition (v) in Rosenblum and van der Laan (2010). There are a few
extra steps required to deal with the fact that we are estimating pj(G = g) with pj,n(G = g).
We first note that we can write
P{ϕ∗zgPn − ϕ∗zg(P∞)}2 = P[{ϕzg(Pn)− ϕzg(P∞)} − EP [ϕzg(P∞)− ϕzg(Pn) |G]]2
≤ 2P{ϕzg(Pn)− ϕzg(P∞)}2 + 2P{EP [ϕzg(P∞)− ϕzg(Pn) |G]}2
≤ 4P{ϕzg(Pn)− ϕzg(P∞)}2 . (39)
The last line comes from applying Jenson’s inequality to the inner expectation of the second
term followed by an application of iterated expectations. We need to show that P{ϕzg(Pn)−
ϕzg(P∞)}2 converges to 0 in probability. In what follows we distinguish the working model
using the fitted parameters βn and the model using the unique maximizer of the expected log-
likelihood β as µˆ1,n and µˆ1,∞, respectively. For brevity, we also let 1zg = 1(Z = z)1(G = g),
p(z) = p(Z = z), pj(g) = pj(G = g), and pj,n(g) = pj,n(G = g). We can write
P{ϕzg(Pn)− ϕzg(P∞)}2
= P
{
1zg
p(z)pj,n(g)
{f(Y )− µˆ1,n(z, g,X)}+ µˆ1,n(z, g,X)− µzg(Pn)
− 1zg
p(z)pj(g)
{f(Y )− µˆ1,∞(z, g,X)} − µˆ1,∞(z, g,X) + µzg(P )
}2
≤ 4
p(z)2
P
{
f(Y )2
}( 1
pj,n(g)
− 1
pj(g)
)2
+
4
p(z)2
P
{
µˆ1,∞(z, g,X)
pj(g)
− µˆ1,n(z, g,X)
pj,n(g)
}2
+ 4P {µˆ1,n(z, g,X)− µˆ1,∞(z, g,X)}2 + 4P {µzg(P )− µzg(Pn)}2
≤ C1
(
1
pj,n(g)
− 1
pj(g)
)2
+
4
p(z)2
P
{
µˆ1,∞(z, g,X)
pj(g)
− µˆ1,n(z, g,X)
pj,n(g)
}2
+ C2||β0 − β||2 + 4{µzg(P )− µzg(Pn)}2 . (40)
The first equality follows immediately from definitions. The first inequality follows from
rearranging terms and noting that (x1 + · · ·+ xk)2 ≤ k(x21 + · · ·+ x2k) by Jensen’s inequality.
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The first term after the second inequality comes from the boundedness of Y . Since pj,n(g)
P→
pj(g) and we have assumed that pj(g) are bounded away from zero, the continuous mapping
theorem implies that this term converges to 0 in probability. The third term comes from
the fact that our working model has uniformly bounded first derivatives. This is due to
the boundedness assumptions on X and the terms of the linear part of our working model.
The conditions given in Proposition 2, are sufficient for βn to converge to β in probability
(Rosenblum and van der Laan (2009), Appendix D). Consequently, the third term also
converges to 0 in probability. The fourth term disappears in probability since we proved
earlier that µzg(Pn) is consistent for µzg(P ). All that is left to handle is the second term. A
little bit of rearranging gives us
4
p(z)2
P
{
µˆ1,∞(z, g,X)
pj(g)
− µˆ1,n(z, g,X)
pj,n(g)
}2
=
4
p(z)2
P
{
µˆ1,∞(z, g,X)− µˆ1,n(z, g,X)
pj(g)
+ µˆ1,n(z, g,X)
(
1
pj,n(g)
− 1
pj(g)
)}2
≤ 8{p(z)pj(g)}2P {µˆ1,∞(z, g,X)− µˆ1,n(z, g,X)}
2
+
8
p(z)2
P
{
µˆ1,n(z, g,X)
2
}( 1
pj,n(g)
− 1
pj(g)
)2
= C3||β0 − β||2 + C4
(
1
pj,n(g)
− 1
pj(g)
)2
. (41)
The first inequality follows again from Jenson’s inequality. The first term in the last line
follows from the same arguments made earlier and the second term follows from the fact
that P {µˆ1,n(z, g,X)2} is bounded. As we’ve already demonstrated, these two terms vanish
in probability. Combining (39), (40), and (41) gives us that P{ϕ∗zg(Pn) − ϕ∗zg(P∞)}2 P→ 0.
(35) follows immediately and an application of Proposition 1 implies that τˆ is also asymp-
totically linear. All that remains is to compute its asymptotic variance.
Asymptotic Variance:
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To compute the asymptotic variance of τˆ we begin with a taylor expansion around τ :
τˆ = 1− µ1(Pn)
µ0(Pn)
= 1− µ1(P )
µ0(P )
− 1
µ0(P )
{µ1(Pn)− µ1(P )}
+
µ1(P )
µ0(P )2
{µ0(Pn)− µ0(P )}+ op
(
1/
√
n
)
= τ − 1
µ0(P )
(Pn − P)ϕ∗1(P∞)(O) +
µ1(P )
µ0(P )2
(Pn − P)ϕ∗0(P∞)(O) + op(1/
√
n) . (42)
The op(1/
√
n) comes from the second order remainder term of the expansion. Using the
expansion in (42) along with the fact that ϕ∗z(P∞)(O) − Pϕ∗z(P∞)(O) are mean zero i.i.d.
random variables we can write the scaled asymptotic variance of τˆ , n · var(τˆ), as
EP
[
µ1(P )
µ0(P )2
(ϕ∗0{P∞)(O)− Pϕ∗0(P∞)(O)} −
1
µ0(P )
{ϕ∗1(P∞)(O)− Pϕ∗1(P∞)(O)}
]2
. (43)
B.5 Additional Simulation Study Details for TMLE-based Estima-
tors
Below are the simulation settings for the individual-specific vaccine and protective effica-
cies (τi and νi), the baseline covariates and how they are transformed when they enter the
condition mean of the distribution of fever counts (Xi, X˜mi , and X˜nmi ), and unobserved het-
erogeneity in the distribution of fever counts between individuals (mi and nmi ).
Generative Distributions:
(1− νi) ∼ (1− ν) exp{−0.052/2} · Lognormal(0, 0.052)
(1− τi) ∼ (1− τ) exp{−0.052/2} · Lognormal(0, 0.052) ,
X˜mi ∼ exp{0.05Xi − 0.052/2} ,
X˜nmi ∼ exp{0.075Xi − 0.0752/2} ,
Xi ∼ Normal(0, 1) ,
mi ∼ exp{−0.052/2} · Lognormal(0, 0.052) ,
nmi ∼ exp{−0.052/2} · Lognormal(0, 0.052) .
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We assume that the spillover efficacy η is equal to zero. Based on empirical evidence and
the negative dependence between malaria-attributable fevers and non-malaria fevers as de-
fined in (1), we simulate the number of malaria-attributable and non-malaria fevers from
negatively dependent negative binomial distributions (Olotu et al., 2013). We use a overdis-
persion parameter of r = 10
Count of malaria-attributable Fevers per child-year:
On the margin, the count of malaria-attributable fevers per child-year follows a negative
binomial distribution with mean µm,i and variance σ2m,i,
1TY mi (z, g) ∼ NB(µm,i, σ2m,i) (44)
where µm,i = κ · (1− νi)g · (1− τi)z · X˜mi · mi and σ2m,i = µ2m,i/r + µm,i.
Count of non-malaria fevers per child-year:
On the margin, the count of non-malaria fevers per child-year follows a negative binomial
distribution with mean µnm,i and variance σ2nm,i,
1TY nmi (z, g) ∼ NB(µnm,i, σ2nm,i) (45)
where µnm,i = φ · X˜nmi · nmi and σ2nm,i = µ2nm,i/r + µnm,i.
Count of fevers of any-cause per child-year:
The joint distribution of the counts of non-malaria and malaria-attributable fevers per
child-year are simulated using a Gaussian copula with a negative dependence parameter
ρ = −0.1 (Genest and Neslehová, 2007).
Specificity and Mendelian Gene Prevalence Settings:
We calibrated κ and φ to achieve different levels of case specificity (s = 0.5 and 0.8).
For example, for a case specificity of 0.8 we set κ and φ so that the expected number of
malaria-attributable fevers is 80% of the expected number of total fevers of any-cause. The
prevalence of the Mendelian gene was set to 20% based on existing estimates of HbAS preva-
lence in sub-Saharan Africa (Ter Kuile et al., 2003; Elguero et al., 2015).
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Initial and Updated Working Model Estimates:
For both the MFD and naive estimators, we used the R function glm.fit from the package
stats to fit the initial estimator µˆ0 in step 1 of Algorithm 1 using Poisson regression. The
regression included main terms for Z, G, and X as well as all interactions.
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